Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 33%
Buy 52%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is expected to continue to experience growth and success in its core immunology franchise, as well as in its recently acquired oncology and aesthetics portfolios. Strong volume growth is expected for key products, such as Rinvoq and Skyrizi, which are also projected to see favorable pricing dynamics. The company's pipeline, specifically in the neuroscience and oncology verticals, has the potential to add additional value to the company's overall portfolio. Risks include competition and pricing pressure, as well as potential delays or setbacks in the development of pipeline assets.

Bears say

AbbVie is facing numerous challenges that could negatively impact its stock performance. The company's key growth drivers, Skyrizi and Rinvoq, are facing strong competition in the immunology space and are expected to see slower growth than previously anticipated. Additionally, the increasing pricing pressure in the oncology segment, specifically on Imbruvica, is expected to continue, which could further impact AbbVie's bottom line. Despite efforts to diversify its portfolio through acquisitions, uncertainties remain around the success of these deals, such as Abivax's potential safety and labeling concerns and the delayed resubmission of TrenibotE for regulatory approval. Overall, the company's near-term financial outlook looks less promising, with a potential downside of 14% from its current stock price.

AbbVie (ABBV) has been analyzed by 21 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 52% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 21 analysts, AbbVie (ABBV) has a Buy consensus rating as of Sep 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $281.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $281.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.